본문 바로가기
KERD
논문KCI 등재

Prognostic Factor and Clinical Outcome in Stage III Non-Small Cell Lung Cancer: A Study Based on Real-World Clinical Data in the Korean Population

송시열|김형렬|최창민|지원준|이재철|Korean Association for Lung Cancer|Korea Central Cancer Registry|김호철
대한암학회 (Korean Cancer Association)|2021.10|Cancer Research and Treatment|제53권 제4호|pp. 1033-1041|DOI 10.4143/crt.2020.1350

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

KoreaSurgeryLung neoplasmsConcurrent chemotherapy and radiation therapy
주제분류의학일반

초록

Purpose The optimal treatment for patients with stage III non–small cell lung cancer (NSCLC) remains controversial. This study aimed to investigate prognostic factors and clinical outcome in stage III NSCLC using real-world clinical data in the Korean population. Materials and Methods Among 8,110 patients with lung cancer selected from 52 hospitals in Korea during 2014-2016, only pati-ents with stage III NSCLC were recruited and analyzed. A standardized protocol was used to collect clinical information and Cox proportional hazards models were used to identify risk factors for mortality. Results A total of 1,383 patients (46.5% had squamous cell carcinoma and 40.9% had adenocarcinoma) with stage III NSCLC were enrolled, and their median age was 70 years. Regarding clinical stage, 548 patients (39.6%) had stage IIIA, 517 (37.4%) had stage IIIB, and 318 (23.0%) had stage IIIC. Pertaining to the initial treatment method, the surgery group (median survival period, 36 months) showed better survival outcomes than the non-surgical treatment group (median survival period, 18 months; p=0.001) in patients with stage IIIA. Moreover, among patients with stage IIIB and stage IIIC, those who received concurrent chemotherapy and radiation therapy (CCRT; median survival period, 24 months) showed better survival outcomes than those who received chemotherapy (median survival period, 11 months), or radiation therapy (median survival period, 10 months; p < 0.001). Conclusion While surgery might be feasible as the initial treatment option in patients with stage IIIA NSCLC, CCRT showed a beneficial role in patients with stage IIIB and IIIC NSCLC.

Abstract

Purpose The optimal treatment for patients with stage III non–small cell lung cancer (NSCLC) remains controversial. This study aimed to investigate prognostic factors and clinical outcome in stage III NSCLC using real-world clinical data in the Korean population. Materials and Methods Among 8,110 patients with lung cancer selected from 52 hospitals in Korea during 2014-2016, only pati-ents with stage III NSCLC were recruited and analyzed. A standardized protocol was used to collect clinical information and Cox proportional hazards models were used to identify risk factors for mortality. Results A total of 1,383 patients (46.5% had squamous cell carcinoma and 40.9% had adenocarcinoma) with stage III NSCLC were enrolled, and their median age was 70 years. Regarding clinical stage, 548 patients (39.6%) had stage IIIA, 517 (37.4%) had stage IIIB, and 318 (23.0%) had stage IIIC. Pertaining to the initial treatment method, the surgery group (median survival period, 36 months) showed better survival outcomes than the non-surgical treatment group (median survival period, 18 months; p=0.001) in patients with stage IIIA. Moreover, among patients with stage IIIB and stage IIIC, those who received concurrent chemotherapy and radiation therapy (CCRT; median survival period, 24 months) showed better survival outcomes than those who received chemotherapy (median survival period, 11 months), or radiation therapy (median survival period, 10 months; p < 0.001). Conclusion While surgery might be feasible as the initial treatment option in patients with stage IIIA NSCLC, CCRT showed a beneficial role in patients with stage IIIB and IIIC NSCLC.

참고문헌 (30)

  1. Barta JA, "Global epidemiology of lung cancer", Ann Glob Health, 85, pp.8~ (2019)
  2. Morgensztern D, "Trends in stage distribution for patients with non-small cell lung cancer : a National Cancer Database survey", J Thorac Oncol, 5, pp.29~33 (2010)
  3. Majem M, "Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer", Clin Transl Oncol, 22, pp.21~36 (2020)
  4. Detterbeck FC, "The IASLC Lung Cancer Staging Project : methodology and validation used in the development of proposals for revision of the stage classification of NSCLC in the forthcoming(Eighth)edition of the TNM classification of lung cancer", J Thorac Oncol, 11, pp.1433~1446 (2016)
  5. Antonia SJ, "Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer", N Engl J Med, 377, pp.1919~1929 (2017)
  6. Rajappa S, "Unmet clinical need in the management of locally advanced unresectable lung cancer : treatment dtrategies to improve patient outcomes", Adv Ther, 36, pp.563~578 (2019)
  7. Bezjak A, "Definitive and adjuvant radiotherapy in loocally advanced non-small-cell lung cancer : American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline", J Clin Oncol, 33, pp.2100~2105 (2015)
  8. Albain KS, "Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer : a phase III randomised controlled trial", Lancet, 374, pp.379~386 (2009)
  9. Zheng D, "Upfront surgery as first-line therapy in selected patients with stage IIIA non-small cell lung cancer", J Thorac Cardiovasc Surg, 155, pp.1814~1822 (2018)
  10. Tan WL, "Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC", J Thorac Oncol, 15, pp.324~343 (2020)
  11. Black K, "Business statistics for contemporary decision making" (2004), Wiley-India
  12. Morgensztern D, "Prognostic significance of tumor size in patients with stage III non-small-cell lung cancer : a surveillance, epidemiology, and end results(SEER)survey from 1998 to 2003", J Thorac Oncol, 7, pp.1479~1484 (2012)
  13. Vinod SK, "Stage III non-small-cell lung cancer : population-based patterns of treatment in British Columbia, Canada", J Thorac Oncol, 7, pp.1155~1163 (2012)
  14. Ademuyiwa FO, "Prognostic factors in stage III non-smallcell lung cancer", Clin Lung Cancer, 8, pp.478~482 (2007)
  15. 이진구, "The Prognostic Significance of Multiple Station N2 in Patients with Surgically Resected Stage IIIA N2 Non-small Cell Lung Cancer", Journal of Korean Medical Science, 23(4), pp.604~608 (2008), 대한의학회
  16. Shepshelovich D, "Body mass index(BMI), BMI change, and overall survival in patients with SCLC and NSCLC : a pooled analysis of the International Lung Cancer Consortium", J Thorac Oncol, 14, pp.1594~1607 (2019)
  17. Goldstraw P, "The IASLC Lung Cancer Staging Project : proposals for revision of the TNM stage groupings in the forthcoming(eighth)edition of the TNM classification for Lung Cancer", J Thorac Oncol, 11, pp.39~51 (2016)
  18. Chansky K, "The IASLC Lung Cancer Staging Project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer", J Thorac Oncol, 12, pp.1109~1121 (2017)
  19. Okami J, "Demographics, safety and quality, and prognostic information in both the seventh and eighth editions of the TNM classification in 18,973 surgical cases of the Japanese Joint Committee of Lung Cancer Registry database in 2010", J Thorac Oncol, 14, pp.212~222 (2019)
  20. Yun JK, "Validation of the 8th edition of the TNM staging system in 3,950patients with surgically resected non-small cell lung cancer", J Thorac Dis, 11, pp.2955~2964 (2019)
  21. Watanabe Y, "Results of surgical treatment in patients with stage IIIA nonsmall-cell lung cancer", Thorac Cardiovasc Surg, 39, pp.44~49 (1991)
  22. van Meerbeeck JP, "Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer", J Natl Cancer Inst, 99, pp.442~450 (2007)
  23. Eberhardt WE, "Phase III study of surgery versus definitive concurrent chemoradiotherapy boost in patients with resectable stage IIIA(N2)and selected IIIB non-small-cell lung cancer after induction chemotherapy and concurrent chemoradiotherapy(ESPATUE)", J Clin Oncol, 33, pp.4194~4201 (2015)
  24. Yun JK, "Long-term outcomes of upfront surgery in patients with resectable pathological N2 non-small-cell lung cancer", Eur J Cardiothorac Surg, 58, pp.59~69 (2020)
  25. McElnay PJ, "Outcome of surgery versus radiotherapy after induction treatment in patients with N2 disease : systematic review and meta-analysis of randomised trials", Thorax, 70, pp.764~768 (2015)
  26. Curran WJ Jr, "Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410", J Natl Cancer Inst, 103, pp.1452~1460 (2011)
  27. Jeremic B, "Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer", J Clin Oncol, 13, pp.452~458 (1995)
  28. Atagi S, "A phase II study of continuous concurrent thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small cell lung cancer", Lung Cancer, 36, pp.105~111 (2002)
  29. Ryan KJ, "Real-world treatment patterns among patients with unresected stage III non-small-cell lung cancer", Future Oncol, 15, pp.2943~2953 (2019)
  30. Horinouchi H, "Real-world outcomes of chemoradiotherapy for unresectable Stage III non-small cell lung cancer : The SOLUTION study", Cancer Med, 9, pp.6597~6608 (2020)

관련 논문AI추천

Active Treatment Improves Overall Survival in Extremely Older Non-Small Cell Lung Cancer Patients: A Multicenter Retrospective Cohort Study이수연, 이재철, 지원준, 최창민, 홍윤기, Korea Central Cancer Registry, Korean Association for Lung Cancer대한암학회 · Cancer Research and Treatment2021 · 제53권 제1호Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung Cancer김보경, 노재명, 박근칠, 박효정, 선종무, 안명주, 안용찬, 안진석, 오동렬, 이언주, 이혜빈, 표홍렬대한암학회 · Cancer Research and Treatment2015 · 제47권 제4호Five-Year Overall Survival and Prognostic Factors in Patients with Lung Cancer: Results from the Korean Association of Lung Cancer Registry (KALC-R) 2015김세희, 김태정, 김호철, 김홍관, 문미형, 백경민, 서양권, 송창훈, 안진석, 이정은, 임정욱, 전다솜, 전재현, 정규원, 정치영, 조정수, 최유덕, 최창민, 황승식, Korea Central Cancer Registry, Korean Association for Lung Cancer대한암학회 · Cancer Research and Treatment2023 · 제55권 제1호Effect of Radiation Therapy Techniques on Outcome in N3-positive IIIB Non-small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy김보경, 김진만, 김진성, 노재명, 박효정, 신정숙, 안용찬, 오동률, 이언주, 주상규, 표홍렬, 홍채선대한암학회 · Cancer Research and Treatment2016 · 제48권 제1호Prognostic outcome of treatment modalities for epidermal growth factor receptor-mutated advanced lung cancerDong Yoon Lee, Jihyeon Jeong, Seung Hun Jang, Won-Il Choi대한내과학회 · The Korean Journal of Internal Medicine2022 · 제37권 제4호Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status윤탁, 김흥태, 남병호, 문성호, 안혜진, 이건국, 이영주, 임건영, 임근영, 한지연대한암학회 · Cancer Research and Treatment2017 · 제49권 제4호

이 간행물의 다른 논문 (30건)

The Law Changes Behaviors: Is It Just Enough?이대호pp. 895-896The Situation of Life-Sustaining Treatment One Year After Enforcement of the Act on Decisions on Life-Sustaining Treatment for Patients at the End-of-Life in Korea: Data of National Agency for Management of Life-Sustaining Treatment백수진, 류혜원, 김화정, 권정혜, 백선경, 원영웅, 김유정, 이하연pp. 897-907Life-Sustaining Treatment States in Korean Cancer Patients After Enforcement of Act on Decisions on Life-Sustaining Treatment for Patients at the End of Life김도연, 류혜원, 김화정, 권정혜, 이하연, 백선경, 원영웅, 김유정pp. 908-916Current Status and Cardinal Features of Patient Autonomy after Enactment of the Life-Sustaining Treatment Decisions Act in Korea권정혜, 원영웅, 김화정, 이하연, 백선경, 류혜원, 김도연, 김유정pp. 917-925Preparation and Practice of the Necessary Documents in Hospital for the “Act on Decision of Life-Sustaining Treatment for Patients at the End-of-Life”김유정, 백선경, 백수진, 김화정, 권정혜, 이하연, 원영웅, 류혜원pp. 926-934
원문 보기